Paper Details

  1. Home
  2. Paper Details

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells.

Author: AngusBrian, BatemanElizabeth A L, BeverleyPeter C, BowmanJaclyn, ClutterbuckElizabeth A, DiggleLinda, LazarusRajeka, MantDavid, PetoTim E, PollardAndrew J, YuLy-Mee

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) is commonly given to adults over 65, but its effectiveness is limited and revaccination leads to weaker antibody responses. It is unclear if pneumococcal polysaccharide-protein conjugated vaccines (PCV), which are highly effective in infants, offer any advantages over 23vP for adults.
Paper Details　
Original Abstract of the Article :
A 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP), routinely administered at the age of 65, has limited effectiveness, and revaccination induces attenuated antibody responses. It is not known whether pneumococcal polysaccharide-protein conjugated vaccines (PCV), although highly eff...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324398/

データ提供：米国国立医学図書館（NLM）

Deciphering the Immunological Landscape of Pneumococcal Vaccines

Pneumococcal vaccines play a crucial role in protecting individuals from pneumococcal infections, but the effectiveness of different vaccine types can vary. This study delves into the immunological differences between two types of pneumococcal vaccines: the 23-valent unconjugated pneumococcal polysaccharide vaccine (23vP) and pneumococcal polysaccharide-protein conjugated vaccines (PCV). The researchers explored the distinct effects of these vaccines on antigen-specific B cells, shedding light on their individual mechanisms of action. Their findings offer insights into the optimal use of these vaccines for different populations.

Unveiling the Immunological Divergence of Pneumococcal Vaccines

The study reveals that 23vP, commonly administered to adults, has limited effectiveness and induces attenuated antibody responses upon revaccination. In contrast, PCV, highly effective in infants, may offer immunological advantages over 23vP in adults. These findings highlight the crucial need for further research to optimize the use of pneumococcal vaccines for different age groups and to explore the potential benefits of PCV in adults.

Understanding the Fine Print of Pneumococcal Vaccines

This study provides valuable insights into the complex immunological landscape of pneumococcal vaccines. Understanding the differences between 23vP and PCV is essential for making informed decisions about vaccine use. Further research is needed to determine the optimal timing and type of pneumococcal vaccine for different populations, ensuring maximum protection against pneumococcal infections.

Dr.Camel's Conclusion

Imagine a desert where the wind whips up sandstorms, making it difficult to see clearly. Pneumococcal vaccines are like shields against these storms, offering protection from harmful bacteria. This research explores the differences between two types of shields, revealing that each one offers unique benefits. Understanding the intricacies of these shields is essential for maximizing protection against these bacterial threats.

Date :
  1. Date Completed 2012-05-31
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22457293

DOI: Digital Object Identifier

PMC3324398

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.